Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA expands use for SpectRx' noninvasive Bilichek:

This article was originally published in Clinica

Executive Summary

SpectRx has received US FDA 510(k) marketing clearance to expand the use of its BiliChek noninvasive test for infant jaundice. The BiliChek device, which assesses bilirubin levels in the skin, can now be used to monitor jaundice during and after treatment for the condition, in addition to its use as a point-of-care screening tool. "The additional claims substantially open the available market for the BiliChek," says Mark Samuels, SpectRx' chairman and CEO. The test is sold in the US by Respironics. More than two million babies are affected by infant jaundice every year in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel